Corrigendum to “Beta-Arrestin 1 Mediates Liver Thyrotropin Regulation of Cholesterol Conversion Metabolism via the Akt-Dependent Pathway”

Shaona Niu,¹,² Hui Li,³ Wenbin Chen,¹,⁴ Jiajun Zhao,¹,⁵ Ling Gao,¹,⁴ and Tao Bo¹,⁴

¹Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China
²Department of Endocrinology, Lin Yi People’s Hospital Affiliated to Shandong University, Linyi, Shandong 276003, China
³Medical College, Shandong University, Jinan, Shandong 250012, China
⁴Scientific Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China
⁵Department of Endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China

Correspondence should be addressed to Tao Bo; botao666666@126.com

Received 19 August 2018; Accepted 27 August 2018; Published 10 September 2018

Copyright © 2018 Shaona Niu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Beta-Arrestin 1 Mediates Liver Thyrotropin Regulation of Cholesterol Conversion Metabolism via the Akt-Dependent Pathway” [1], the first affiliation was incomplete. The correct affiliation is shown above.

References
